Background: The accumulation of fat droplets in the hepatic parenchyma is driven by several factors, synergistically acting to increase triglyceride flow to the liver (diet and metabolic factors, endotoxemia from gut microbiota, genetic factors). Key Messages: In the presence of unhealthy lifestyles and behavioral factors, leading to enlarged adipose tissue and insulin resistance (IR), both lipolysis and de novo lipogenesis are expected to increase the risk of hepatic lipid depots, in association with high calorie (either high-fat or high-carbohydrate) diets. The gut microbiota may also be involved via obesity, IR and hepatic inflammation generated by gut-derived toxic factors. Finally, several data also support a primary role of genetic factors. A few gene polymorphisms have also been associated with the risk of nonalcoholic fatty liver disease development and nonalcoholic steatohepatitis progression to more fibrosis and advanced liver disease. In a few cases (e.g., patatin-like phospholipase domain-containing 3/adiponutrin), steatosis carries a high risk of both liver disease and cardiovascular morbidity/mortality; in other cases (e.g., transmembrane 6 superfamily 2 human gene), dissociation has been observed between the increased risk of liver disease versus cardiovascular disease. Conclusions: A variable interplay between the genetic background and the metabolic milieu is the likely physiopathologic mechanism involved in individual cases, which must be considered for implementing effective treatment strategies.

Journal Section:
Nonalcoholic Fatty Liver Disease
Keywords:
Diet, Genes, Microbiota, Nonalcoholic fatty liver disease, Obesity
1.
Marchesini G, Babini M: Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol 2006;54:229-239.
2.
Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P: Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015;47:181-190.
3.
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
4.
Jacome-Sosa MM, Parks EJ: Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans. Curr Opin Lipidol 2014;25:213-220.
5.
Bugianesi E, McCullough AJ, Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000.
6.
Cowart LA: Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 2009;20:34-42.
7.
Bikman BT, Summers SA: Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011;121:4222-4230.
8.
Savage DB, Semple RK: Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 2010;21:329-336.
9.
Rinella ME: Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-2273.
10.
Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, De Iasio R, et al: Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498-3504.
11.
Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867.
12.
Marchesini G, Pagotto U, Bugianesi E, De Iasio R, Manini R, Vanni E, et al: Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J Clin Endocrinol Metab 2003;88:5674-5679.
13.
Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S: Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br J Nutr 2013;109:1096-1104.
14.
Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A, et al: Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90:2804-2809.
15.
Longato L, Tong M, Wands JR, de la Monte SM: High fat diet induced hepatic steatosis and insulin resistance: role of dysregulated ceramide metabolism. Hepatol Res 2012;42:412-427.
16.
Browning JD, Davis J, Saboorian MH, Burgess SC: A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. Hepatology 2006;44:487-488.
17.
Vos MB, Lavine JE: Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013;57:2525-2531.
18.
Marchesini G, Ridolfi V, Nepoti V: Hepatotoxicity of fast food? Gut 2008;57:568-570.
19.
Marchesini G, Petta S, Dalle Grave R: Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice. Hepatology 2016;63:2032-2043.
20.
Marchesini G, Mazzella N, Forlani G: Weight loss for a healthy liver. Gastroenterology 2015;149:274-278.
21.
Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al: Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011;94:58-65.
22.
Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al: Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013;58:120-127.
23.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031.
24.
Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al: Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-609.
25.
Zhu L, Baker RD, Baker SS: Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res 2015;77:245-251.
26.
Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al: Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11:868-875.e1-e3.
27.
De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, et al: Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 2014;59:1738-1749.
28.
Boursier J, Diehl AM: Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog 2015;11:e1004559.
29.
Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-1887.
30.
Gabele E, Dostert K, Hofmann C, Wiest R, Scholmerich J, Hellerbrand C, et al: DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011;55:1391-1399.
31.
Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, et al: Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010;7:15.
32.
Alisi A, Manco M, Devito R, Piemonte F, Nobili V: Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010;50:645-649.
33.
Wieland A, Frank DN, Harnke B, Bambha K: Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2015;42:1051-1063.
34.
Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al: Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006;103:12511-12516.
35.
Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA: Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011;140:976-986.
36.
Schaap FG, Trauner M, Jansen PL: Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014;11:55-67.
37.
Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, et al: Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A 2011;108(suppl 1):4523-4530.
38.
Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, et al: Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015;125:386-402.
39.
Abu-Shanab A, Quigley EM: The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:691-701.
40.
Engstler AJ, Aumiller T, Degen C, Durr M, Weiss E, Maier IB, et al: Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut 2015;pii:gutjnl-2014-308379.
41.
Dongiovanni P, Anstee QM, Valenti L: Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013;19:5219-5238.
42.
Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, et al: Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 2015;149:1784-1793.
43.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
44.
Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, et al: Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006;103:18273-18277.
45.
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
46.
Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al: Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
47.
Petta S, Grimaudo S, Camma C, Cabibi D, Di Marco V, Licata G, et al: IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012;56:1356-1362.
48.
Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al: Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-1217.
49.
Van Vre EA, Ait-Oufella H, Tedgui A, Mallat Z: Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:887-893.
50.
Petta S, Valenti L, Marchesini G, Di Marco V, Licata A, Camma C, et al: PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One 2013;8:e74089.
51.
Speliotes EK, Butler JL, Palmer CD, Voight BF; GIANT Consortium; MIGen Consortium, et al: PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010;52:904-912.
52.
Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al: Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61:506-514.
53.
Hernaez R, McLean J, Lazo M, Brancati FL, Hirschhorn JN, Borecki IB, et al: Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third national health and nutrition examination survey. Clin Gastroenterol Hepatol 2013;11:1183-1190.e2.
54.
Petta S, Miele L, Bugianesi E, Camma C, Rosso C, Boccia S, et al: Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2014;9:e87523.
55.
Peter A, Stefan N, Cegan A, Walenta M, Wagner S, Konigsrainer A, et al: Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 2011;96:E1126-E1130.
56.
Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E, et al: MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. J Hepatol 2016;64:682-690.
57.
Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, et al: Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010;362:1082-1089.
58.
Agius L: Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414:1-18.
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.